Clinical-Pharmacology-graph_Large-molecule_web
Alta Sciences
JANUARY 23, 2024
Clinical-Pharmacology-graph_Large-molecule_web ehdem Tue, 01/23/2024 - 14:06 Image Clinical-Pharmacology-graph_Large-molecule_web.png Weight 1
Alta Sciences
JANUARY 23, 2024
Clinical-Pharmacology-graph_Large-molecule_web ehdem Tue, 01/23/2024 - 14:06 Image Clinical-Pharmacology-graph_Large-molecule_web.png Weight 1
Alta Sciences
MAY 28, 2024
Altasciences Receives 2024 CRO Leadership Award for Capabilities aasimakopoulos Wed, 05/29/2024 - 17:54 Laval, Québec, May 29, 2024 – Altasciences announced today that it has been recognized for excellence in contract research with a 2024 CRO Leadership Award for Capabilities.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Agency IQ
MAY 3, 2024
What We Expect the FDA to do in May and June 2024 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.
Alta Sciences
JANUARY 23, 2024
Altasciences Appoints New General Manager, Clinical Operations pmjackson Tue, 01/23/2024 - 19:52 Laval, Québec, Monday, January 29, 2024 — Altasciences announced the appointment of James Brazeal as General Manager, Clinical Operations, at its clinical facility in Kansas City.
Agency IQ
FEBRUARY 2, 2024
What We Expect the FDA to do in February and March 2024 (Updated) In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.
Agency IQ
MARCH 1, 2024
What We Expect the FDA to do in March and April 2024 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.
Alta Sciences
FEBRUARY 8, 2024
Utilizing 10 state-of-the-art simulators available in-house at our Montréal clinical facility (with the capacity for more than 20), we are equipped to measure a range of studies; from impairment in cognition and comparing compounds to assessing the impact on new formulations have on impairment.
Let's personalize your content